Listed

Fate Therapeutics Inc

FATENasdaqCIK 1434316HealthcareFiscal year ends Dec 31

Reports and events: 227 filings

Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.

What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.

Fate Therapeutics Inc, Reports and events
FiledFormWhat it isAccession number
2023-11-0817:10 ET8-K1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits0001193125-23-273633
2023-11-0816:05 ET10-QQuarterly reportPeriod 2023-09-300000950170-23-061080
2023-11-0816:03 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000950170-23-061077
2023-09-0117:29 ET8-K8.01 Other events0001193125-23-227749
2023-08-0816:09 ET10-QQuarterly reportPeriod 2023-06-300000950170-23-039803
2023-08-0816:07 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000950170-23-039783
2023-06-0916:08 ET8-K5.07 Shareholder vote results0000950170-23-027262
2023-06-0816:12 ET8-K5.02 Departure or appointment of officers or directors0000950170-23-027007
2023-06-0708:52 ET8-K8.01 Other events0000950170-23-026747
2023-05-0316:10 ET10-QQuarterly reportPeriod 2023-03-310000950170-23-017175
2023-05-0316:06 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000950170-23-017157
2023-04-2116:04 ETDEF 14AProxy statement0001193125-23-110475
2023-04-1917:15 ETSC 13D/AOwnership report, active investor, amended0001104659-23-047252
2023-04-1916:06 ET8-K3.01 Delisting notice; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits0000950170-23-013471
2023-02-2816:06 ET10-KAnnual reportPeriod 2022-12-310000950170-23-005067
2023-02-2816:03 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000950170-23-005063
2023-01-0517:04 ET8-K1.02 Termination of a material agreement; 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits0001193125-23-002504
2022-11-0713:21 ET8-K1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000950170-22-022488
2022-11-0316:05 ET10-QQuarterly reportPeriod 2022-09-300000950170-22-021840
2022-11-0316:03 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000950170-22-021834
2022-08-0316:08 ET10-QQuarterly reportPeriod 2022-06-300000950170-22-014236
2022-08-0316:03 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000950170-22-014223
2022-06-3016:06 ET8-K1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000950170-22-012381
2022-06-1316:10 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0000950170-22-011554
2022-05-0416:16 ET10-QQuarterly reportPeriod 2022-03-310000950170-22-007389
2022-05-0416:06 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000950170-22-007377
2022-04-2516:03 ETDEF 14AProxy statementPeriod 2022-06-090001193125-22-117516
2022-02-2816:13 ET10-KAnnual reportPeriod 2021-12-310000950170-22-002293
2022-02-2816:06 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000950170-22-002285
2021-12-1417:28 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-21-356947
2021-11-0416:59 ET8-K1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits0001193125-21-320325
2021-11-0416:13 ET10-QQuarterly reportPeriod 2021-09-300000950170-21-003066
2021-11-0416:07 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000950170-21-003055
2021-08-0416:13 ET10-QQuarterly reportPeriod 2021-06-300001564590-21-040821
2021-08-0416:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001564590-21-040793
2021-08-0409:20 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-21-235830
2021-06-0716:50 ET8-K5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001193125-21-184402
2021-05-0516:07 ET10-QQuarterly reportPeriod 2021-03-310001564590-21-024037
2021-05-0516:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001564590-21-024017
2021-04-2116:11 ETDEF 14AProxy statementPeriod 2021-06-020001193125-21-124699
2021-03-2516:01 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001564590-21-015473
2021-02-2416:09 ET10-KAnnual reportPeriod 2020-12-310001564590-21-008086
2021-02-2416:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001564590-21-008069
2021-01-1216:18 ETSC 13D/AOwnership report, active investor, amended0001104659-21-003451
2021-01-0816:02 ET8-K1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits0001193125-21-005180
2020-12-2216:01 ET8-K5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits0001564590-20-058034
2020-12-0709:00 ET8-K8.01 Other events0001564590-20-056247
2020-11-0516:07 ET10-QQuarterly reportPeriod 2020-09-300001564590-20-051301
2020-11-0516:02 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001564590-20-051284
2020-08-1916:01 ET8-K5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001564590-20-040672

Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 14, 2026, 10:50 ET. Listed shows no prices and gives no investment advice.